BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/12/2017 6:45:23 AM | Browse: 1392 | Download: 2936
 |
Received |
|
2017-01-17 09:47 |
|
Peer-Review Started |
|
2017-01-18 19:37 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2017-02-14 11:39 |
|
Revised |
|
2017-03-08 14:12 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2017-06-09 05:21 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2017-06-12 08:34 |
|
Articles in Press |
|
2017-06-12 08:34 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2017-07-03 08:45 |
|
Publish the Manuscript Online |
|
2017-07-12 06:45 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety
|
| Manuscript Source |
Invited Conference Manuscripts |
| All Author List |
Nyan L Latt, Beshoy T Yanny, Derenik Gharibian, Rita Gevorkyan and Amandeep K Sahota |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nyan L Latt, MD, Transplant Hepatology Fellow, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, United States. latt.nyan@mayo.edu |
| Key Words |
Hepatitis C; sustained viral response; ledipasvir; cirrhosis; sofosbuvir |
| Core Tip |
We highlight that sustained viral response (SVR) outcomes in patients with their non-cirrhotic status determined by clinical judgment using simple, cheap, non-invasive tests such as platelet count, sonographic finding of spleen size and hepatic morphology, are comparable with those who had specialized tests such as liver biopsy, vibration-controlled transient elastography or specialized serum biomarker test. We also validate the fact that hepatitis C virus (HCV) RNA plays a role in predicting SVR (AUROC = 0.743, 95%CI: 0.66-0.82) with a cutoff value of 2.2 million IU/mL. Significantly higher 98% SVR was observed among HCV RNA < 2.2 million IU/mL, compared to 92% SVR with HCV RNA ≥ 2.2 million IU/mL. |
| Publish Date |
2017-07-12 06:45 |
| Citation |
Latt NL, Yanny BT, Gharibian D, Gevorkyan R, Sahota AK. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million IU/mL: Single center, real world effectiveness and safety. World J Gastroenterol 2017; 23(26): 4759-4766 |
| URL |
http://www.wjgnet.com/1007-9327/full/v23/i26/4759.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v23.i26.4759 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
